Report Detail
Global Genetic Obesity Drug Market Insights, Forecast to 2028
- RnM4444265 |
- 24 May, 2022 |
- Global |
- 113 Pages |
- QYResearch |
- Pharma & Healthcare
Summary:
Market Analysis and Insights: Global Genetic Obesity Drug Market
Obesity, a condition in which body fat levels are elevated to extreme extent, is a common disorder. Obesity is a condition caused by the lower levels of the metabolism rate.The current advancement in Genetic Obesity Drugs in rapidly recovering the appetite inhibiting hormone level in the body is anticipated to increase the adoption of Genetic obesity drugs in physicians.
The global Genetic Obesity Drug market size is projected to reach US$ million by 2028, from US$ million in 2021, at a CAGR of % during 2022-2028.
Fully considering the economic change by this health crisis, Sibutramine accounting for % of the Genetic Obesity Drug global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Hospitals Pharmacy segment is altered to an % CAGR throughout this forecast period.
China Genetic Obesity Drug market size is valued at US$ million in 2021, while the North America and Europe Genetic Obesity Drug are US$ million and US$ million, severally. The proportion of the North America is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period 2022-2028. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Genetic Obesity Drug landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period 2022-2028.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Genetic Obesity Drug market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Genetic Obesity Drug market in terms of revenue.
Overall, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Genetic Obesity Drug market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Genetic Obesity Drug market.
Impact of Covid-19 Outbreak
This section of the report has explored the overall status of the Covid scenario and has offered valuable insights into the changes in supply chain disruption, fluctuations in demand, etc. The analysts have also focused on the key measures that the companies are opting to withstand the harsh scenario.
Segmental Analysis
The report has been segmented into product and application segments. The researchers have documented all the products present today in the Genetic Obesity Drug market. They have also shed light on the new product innovations and launches by the key players. In the segmental analysis, the analysts have provided revenue forecast figures based on type and application for the period 2017-2028. They have also discussed about the growth rate and potential of each segment for the period 2017-2028.
Genetic Obesity Drug Breakdown Data by Drug Type
Sibutramine
Orlistat
Sympathomimetic Drugs
Receptors Antagonists
Others
Genetic Obesity Drug Breakdown Data by Application
Hospitals Pharmacy
Retail Pharmacy
Online Pharmacy
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Competitive Landscape
This segment focuses on the key players operating in the industry. It underlines all the current and future activities by the prominent manufacturers. By understanding various initiatives being taken up by different players, readers will gain the ability to settle on correct business choices. The authors of the report have provided accurate revenue figures of the companies for the period 2017-2022. The clients are sure to gain the upper hand once they get hold of this report. Key players studied in the research report include:
Pfizer, Inc.
Sanofi.
Tonghua Dongbao Pharmaceutical Co., Ltd.
Biocon.
Adocia
GlaxoSmithKline Plc.
Novo Nordisk A/S.
Oramed Pharmaceuticals, Inc
Wockhardt.
Eli Lilly and Company.
Merck & Co., Inc.
Julphar.
Bristol-Myers Squibb Company.
Frequently Asked Questions
What factors will challenge the Genetic Obesity Drug market growth?
Which end-use segment will expand at the fastest CAGR in the Genetic Obesity Drug market?
Which are the emerging players in the Genetic Obesity Drug market?
How concentrated is the Genetic Obesity Drug market?
Which factors are positively contributing to the Genetic Obesity Drug market growth?
Which are the novel product innovations in the Genetic Obesity Drug market?
Which product segment will emerge as the most lucrative in the Genetic Obesity Drug market?
Which factors are increasing the competition in the Genetic Obesity Drug market?
Which are the strategic measures taken by the Genetic Obesity Drug industry players?
Which region will witness inactive growth during the forecast period?
What key trends are likely to emerge in the Genetic Obesity Drug market in the coming years?
Table of Contents
1 Report Business Overview
- 1.1 Study Scope
- 1.2 Market Analysis by Drug Type
- 1.2.1 Global Genetic Obesity Drug Market Size Growth Rate by Drug Type, 2017 VS 2021 VS 2028
- 1.2.2 Sibutramine
- 1.2.3 Orlistat
- 1.2.4 Sympathomimetic Drugs
- 1.2.5 Receptors Antagonists
- 1.2.6 Others
- 1.3 Market by Application
- 1.3.1 Global Genetic Obesity Drug Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
- 1.3.2 Hospitals Pharmacy
- 1.3.3 Retail Pharmacy
- 1.3.4 Online Pharmacy
- 1.3.5 Others
- 1.4 Study Objectives
- 1.5 Years Considered
2 Global Growth Trends
- 2.1 Global Genetic Obesity Drug Market Perspective (2017-2028)
- 2.2 Genetic Obesity Drug Growth Trends by Region
- 2.2.1 Genetic Obesity Drug Market Size by Region: 2017 VS 2021 VS 2028
- 2.2.2 Genetic Obesity Drug Historic Market Size by Region (2017-2022)
- 2.2.3 Genetic Obesity Drug Forecasted Market Size by Region (2023-2028)
- 2.3 Genetic Obesity Drug Market Dynamics
- 2.3.1 Genetic Obesity Drug Industry Trends
- 2.3.2 Genetic Obesity Drug Market Drivers
- 2.3.3 Genetic Obesity Drug Market Challenges
- 2.3.4 Genetic Obesity Drug Market Restraints
3 Competition Landscape by Key Players
- 3.1 Global Top Genetic Obesity Drug Players by Revenue
- 3.1.1 Global Top Genetic Obesity Drug Players by Revenue (2017-2022)
- 3.1.2 Global Genetic Obesity Drug Revenue Market Share by Players (2017-2022)
- 3.2 Global Genetic Obesity Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
- 3.3 Players Covered: Ranking by Genetic Obesity Drug Revenue
- 3.4 Global Genetic Obesity Drug Market Concentration Ratio
- 3.4.1 Global Genetic Obesity Drug Market Concentration Ratio (CR5 and HHI)
- 3.4.2 Global Top 10 and Top 5 Companies by Genetic Obesity Drug Revenue in 2021
- 3.5 Genetic Obesity Drug Key Players Head office and Area Served
- 3.6 Key Players Genetic Obesity Drug Product Solution and Service
- 3.7 Date of Enter into Genetic Obesity Drug Market
- 3.8 Mergers & Acquisitions, Expansion Plans
4 Genetic Obesity Drug Breakdown Data by Drug Type
- 4.1 Global Genetic Obesity Drug Historic Market Size by Drug Type (2017-2022)
- 4.2 Global Genetic Obesity Drug Forecasted Market Size by Drug Type (2023-2028)
5 Genetic Obesity Drug Breakdown Data by Application
- 5.1 Global Genetic Obesity Drug Historic Market Size by Application (2017-2022)
- 5.2 Global Genetic Obesity Drug Forecasted Market Size by Application (2023-2028)
6 North America
- 6.1 North America Genetic Obesity Drug Market Size (2017-2028)
- 6.2 North America Genetic Obesity Drug Market Size by Drug Type
- 6.2.1 North America Genetic Obesity Drug Market Size by Drug Type (2017-2022)
- 6.2.2 North America Genetic Obesity Drug Market Size by Drug Type (2023-2028)
- 6.2.3 North America Genetic Obesity Drug Market Share by Drug Type (2017-2028)
- 6.3 North America Genetic Obesity Drug Market Size by Application
- 6.3.1 North America Genetic Obesity Drug Market Size by Application (2017-2022)
- 6.3.2 North America Genetic Obesity Drug Market Size by Application (2023-2028)
- 6.3.3 North America Genetic Obesity Drug Market Share by Application (2017-2028)
- 6.4 North America Genetic Obesity Drug Market Size by Country
- 6.4.1 North America Genetic Obesity Drug Market Size by Country (2017-2022)
- 6.4.2 North America Genetic Obesity Drug Market Size by Country (2023-2028)
- 6.4.3 United States
- 6.4.4 Canada
7 Europe
- 7.1 Europe Genetic Obesity Drug Market Size (2017-2028)
- 7.2 Europe Genetic Obesity Drug Market Size by Drug Type
- 7.2.1 Europe Genetic Obesity Drug Market Size by Drug Type (2017-2022)
- 7.2.2 Europe Genetic Obesity Drug Market Size by Drug Type (2023-2028)
- 7.2.3 Europe Genetic Obesity Drug Market Share by Drug Type (2017-2028)
- 7.3 Europe Genetic Obesity Drug Market Size by Application
- 7.3.1 Europe Genetic Obesity Drug Market Size by Application (2017-2022)
- 7.3.2 Europe Genetic Obesity Drug Market Size by Application (2023-2028)
- 7.3.3 Europe Genetic Obesity Drug Market Share by Application (2017-2028)
- 7.4 Europe Genetic Obesity Drug Market Size by Country
- 7.4.1 Europe Genetic Obesity Drug Market Size by Country (2017-2022)
- 7.4.2 Europe Genetic Obesity Drug Market Size by Country (2023-2028)
- 7.4.3 Germany
- 7.4.4 France
- 7.4.5 U.K.
- 7.4.6 Italy
- 7.4.7 Russia
- 7.4.8 Nordic Countries
8 Asia-Pacific
- 8.1 Asia-Pacific Genetic Obesity Drug Market Size (2017-2028)
- 8.2 Asia-Pacific Genetic Obesity Drug Market Size by Drug Type
- 8.2.1 Asia-Pacific Genetic Obesity Drug Market Size by Drug Type (2017-2022)
- 8.2.2 Asia-Pacific Genetic Obesity Drug Market Size by Drug Type (2023-2028)
- 8.2.3 Asia-Pacific Genetic Obesity Drug Market Share by Drug Type (2017-2028)
- 8.3 Asia-Pacific Genetic Obesity Drug Market Size by Application
- 8.3.1 Asia-Pacific Genetic Obesity Drug Market Size by Application (2017-2022)
- 8.3.2 Asia-Pacific Genetic Obesity Drug Market Size by Application (2023-2028)
- 8.3.3 Asia-Pacific Genetic Obesity Drug Market Share by Application (2017-2028)
- 8.4 Asia-Pacific Genetic Obesity Drug Market Size by Region
- 8.4.1 Asia-Pacific Genetic Obesity Drug Market Size by Region (2017-2022)
- 8.4.2 Asia-Pacific Genetic Obesity Drug Market Size by Region (2023-2028)
- 8.4.3 China
- 8.4.4 Japan
- 8.4.5 South Korea
- 8.4.6 Southeast Asia
- 8.4.7 India
- 8.4.8 Australia
9 Latin America
- 9.1 Latin America Genetic Obesity Drug Market Size (2017-2028)
- 9.2 Latin America Genetic Obesity Drug Market Size by Drug Type
- 9.2.1 Latin America Genetic Obesity Drug Market Size by Drug Type (2017-2022)
- 9.2.2 Latin America Genetic Obesity Drug Market Size by Drug Type (2023-2028)
- 9.2.3 Latin America Genetic Obesity Drug Market Share by Drug Type (2017-2028)
- 9.3 Latin America Genetic Obesity Drug Market Size by Application
- 9.3.1 Latin America Genetic Obesity Drug Market Size by Application (2017-2022)
- 9.3.2 Latin America Genetic Obesity Drug Market Size by Application (2023-2028)
- 9.3.3 Latin America Genetic Obesity Drug Market Share by Application (2017-2028)
- 9.4 Latin America Genetic Obesity Drug Market Size by Country
- 9.4.1 Latin America Genetic Obesity Drug Market Size by Country (2017-2022)
- 9.4.2 Latin America Genetic Obesity Drug Market Size by Country (2023-2028)
- 9.4.3 Mexico
- 9.4.4 Brazil
10 Middle East & Africa
- 10.1 Middle East & Africa Genetic Obesity Drug Market Size (2017-2028)
- 10.2 Middle East & Africa Genetic Obesity Drug Market Size by Drug Type
- 10.2.1 Middle East & Africa Genetic Obesity Drug Market Size by Drug Type (2017-2022)
- 10.2.2 Middle East & Africa Genetic Obesity Drug Market Size by Drug Type (2023-2028)
- 10.2.3 Middle East & Africa Genetic Obesity Drug Market Share by Drug Type (2017-2028)
- 10.3 Middle East & Africa Genetic Obesity Drug Market Size by Application
- 10.3.1 Middle East & Africa Genetic Obesity Drug Market Size by Application (2017-2022)
- 10.3.2 Middle East & Africa Genetic Obesity Drug Market Size by Application (2023-2028)
- 10.3.3 Middle East & Africa Genetic Obesity Drug Market Share by Application (2017-2028)
- 10.4 Middle East & Africa Genetic Obesity Drug Market Size by Country
- 10.4.1 Middle East & Africa Genetic Obesity Drug Market Size by Country (2017-2022)
- 10.4.2 Middle East & Africa Genetic Obesity Drug Market Size by Country (2023-2028)
- 10.4.3 Turkey
- 10.4.4 Saudi Arabia
- 10.4.5 UAE
11 Key Players Profiles
- 11.1 Pfizer, Inc.
- 11.1.1 Pfizer, Inc. Company Details
- 11.1.2 Pfizer, Inc. Business Overview
- 11.1.3 Pfizer, Inc. Genetic Obesity Drug Introduction
- 11.1.4 Pfizer, Inc. Revenue in Genetic Obesity Drug Business (2017-2022)
- 11.1.5 Pfizer, Inc. Recent Developments
- 11.2 Sanofi.
- 11.2.1 Sanofi. Company Details
- 11.2.2 Sanofi. Business Overview
- 11.2.3 Sanofi. Genetic Obesity Drug Introduction
- 11.2.4 Sanofi. Revenue in Genetic Obesity Drug Business (2017-2022)
- 11.2.5 Sanofi. Recent Developments
- 11.3 Tonghua Dongbao Pharmaceutical Co., Ltd.
- 11.3.1 Tonghua Dongbao Pharmaceutical Co., Ltd. Company Details
- 11.3.2 Tonghua Dongbao Pharmaceutical Co., Ltd. Business Overview
- 11.3.3 Tonghua Dongbao Pharmaceutical Co., Ltd. Genetic Obesity Drug Introduction
- 11.3.4 Tonghua Dongbao Pharmaceutical Co., Ltd. Revenue in Genetic Obesity Drug Business (2017-2022)
- 11.3.5 Tonghua Dongbao Pharmaceutical Co., Ltd. Recent Developments
- 11.4 Biocon.
- 11.4.1 Biocon. Company Details
- 11.4.2 Biocon. Business Overview
- 11.4.3 Biocon. Genetic Obesity Drug Introduction
- 11.4.4 Biocon. Revenue in Genetic Obesity Drug Business (2017-2022)
- 11.4.5 Biocon. Recent Developments
- 11.5 Adocia
- 11.5.1 Adocia Company Details
- 11.5.2 Adocia Business Overview
- 11.5.3 Adocia Genetic Obesity Drug Introduction
- 11.5.4 Adocia Revenue in Genetic Obesity Drug Business (2017-2022)
- 11.5.5 Adocia Recent Developments
- 11.6 GlaxoSmithKline Plc.
- 11.6.1 GlaxoSmithKline Plc. Company Details
- 11.6.2 GlaxoSmithKline Plc. Business Overview
- 11.6.3 GlaxoSmithKline Plc. Genetic Obesity Drug Introduction
- 11.6.4 GlaxoSmithKline Plc. Revenue in Genetic Obesity Drug Business (2017-2022)
- 11.6.5 GlaxoSmithKline Plc. Recent Developments
- 11.7 Novo Nordisk A/S.
- 11.7.1 Novo Nordisk A/S. Company Details
- 11.7.2 Novo Nordisk A/S. Business Overview
- 11.7.3 Novo Nordisk A/S. Genetic Obesity Drug Introduction
- 11.7.4 Novo Nordisk A/S. Revenue in Genetic Obesity Drug Business (2017-2022)
- 11.7.5 Novo Nordisk A/S. Recent Developments
- 11.8 Oramed Pharmaceuticals, Inc
- 11.8.1 Oramed Pharmaceuticals, Inc Company Details
- 11.8.2 Oramed Pharmaceuticals, Inc Business Overview
- 11.8.3 Oramed Pharmaceuticals, Inc Genetic Obesity Drug Introduction
- 11.8.4 Oramed Pharmaceuticals, Inc Revenue in Genetic Obesity Drug Business (2017-2022)
- 11.8.5 Oramed Pharmaceuticals, Inc Recent Developments
- 11.9 Wockhardt.
- 11.9.1 Wockhardt. Company Details
- 11.9.2 Wockhardt. Business Overview
- 11.9.3 Wockhardt. Genetic Obesity Drug Introduction
- 11.9.4 Wockhardt. Revenue in Genetic Obesity Drug Business (2017-2022)
- 11.9.5 Wockhardt. Recent Developments
- 11.10 Eli Lilly and Company.
- 11.10.1 Eli Lilly and Company. Company Details
- 11.10.2 Eli Lilly and Company. Business Overview
- 11.10.3 Eli Lilly and Company. Genetic Obesity Drug Introduction
- 11.10.4 Eli Lilly and Company. Revenue in Genetic Obesity Drug Business (2017-2022)
- 11.10.5 Eli Lilly and Company. Recent Developments
- 11.11 Merck & Co., Inc.
- 11.11.1 Merck & Co., Inc. Company Details
- 11.11.2 Merck & Co., Inc. Business Overview
- 11.11.3 Merck & Co., Inc. Genetic Obesity Drug Introduction
- 11.11.4 Merck & Co., Inc. Revenue in Genetic Obesity Drug Business (2017-2022)
- 11.11.5 Merck & Co., Inc. Recent Developments
- 11.12 Julphar.
- 11.12.1 Julphar. Company Details
- 11.12.2 Julphar. Business Overview
- 11.12.3 Julphar. Genetic Obesity Drug Introduction
- 11.12.4 Julphar. Revenue in Genetic Obesity Drug Business (2017-2022)
- 11.12.5 Julphar. Recent Developments
- 11.13 Bristol-Myers Squibb Company.
- 11.13.1 Bristol-Myers Squibb Company. Company Details
- 11.13.2 Bristol-Myers Squibb Company. Business Overview
- 11.13.3 Bristol-Myers Squibb Company. Genetic Obesity Drug Introduction
- 11.13.4 Bristol-Myers Squibb Company. Revenue in Genetic Obesity Drug Business (2017-2022)
- 11.13.5 Bristol-Myers Squibb Company. Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
- 13.1 Research Methodology
- 13.1.1 Methodology/Research Approach
- 13.1.2 Data Source
- 13.2 Author Details
Summary:
Get latest Market Research Reports on Genetic Obesity Drug. Industry analysis & Market Report on Genetic Obesity Drug is a syndicated market report, published as Global Genetic Obesity Drug Market Insights, Forecast to 2028. It is complete Research Study and Industry Analysis of Genetic Obesity Drug market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
